Vivimed Labs Ltd Locks at Upper Circuit With 5.33% Peak — Buyers Queue, Sellers Absent

Circuit Event and Unfilled Demand

The stock of Vivimed Labs Ltd hit its upper circuit price limit of Rs 5.33 on 3 Aug 2026, representing a 5% gain from the previous close. The 5% price band capped the daily upside, effectively freezing trading at the ceiling price. This scenario indicates unfilled demand, where buyers were willing to purchase more shares but no sellers were prepared to sell at or below this price. The total traded volume stood at 2.32 lakh shares, with a turnover of approximately Rs 0.12 crore, reflecting the mechanical suppression of volume typical on circuit days. Vivimed Labs Ltd’s session exemplifies how the exchange’s price band can limit price discovery despite persistent buying interest — what does the full demand picture look like for Vivimed Labs Ltd once the circuit unlocks and normal trading resumes?

Delivery and Volume Analysis

Delivery volumes provide a crucial lens to assess the quality of the upper circuit move. On 31 Jul 2026, delivery volume surged to 24,560 shares, a remarkable 269.55% increase against the 5-day average delivery volume. This spike in delivery suggests that the shares traded were largely taken into investors’ demat accounts, signalling genuine buying conviction rather than intraday speculative trading. However, the total traded volume on the circuit day was relatively modest, which is consistent with the price lock mechanism that restricts liquidity. The delivery data is the most revealing metric on a circuit day — does Vivimed Labs Ltd’s fundamental and technical data support the buying pressure?

Moving Averages and Trend Context

Despite the upper circuit gain, Vivimed Labs Ltd remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning indicates that the stock is still in a broader downtrend and the circuit move represents a short-term price spike rather than a confirmed trend reversal. The stock’s last traded price of Rs 5.15 is still 3.7% above its 52-week low of Rs 4.94, suggesting some recovery from recent lows but no sustained momentum yet. The 5% price band means the stock gained the maximum allowed in a single session — is Vivimed Labs Ltd’s 5% surge backed by improving fundamentals or is this a liquidity-driven micro-cap move?

Liquidity and Market Capitalisation Context

With a market capitalisation of approximately Rs 43 crore, Vivimed Labs Ltd is classified as a micro-cap stock. The liquidity profile is limited, with the stock liquid enough for a trade size of effectively Rs 0 crore based on 2% of the 5-day average traded value. This extremely thin liquidity means that even modest buying or selling interest can cause significant price swings and trigger circuit limits. The upper circuit is impressive in percentage terms, but the ability to enter or exit a position of meaningful size is severely constrained. For micro-cap stocks like this, liquidity risk is as important as the momentum signal — should investors be cautious about chasing Vivimed Labs Ltd given its limited liquidity?

Intraday Price Action

The intraday range on 3 Aug 2026 was relatively narrow, with a low of Rs 4.98 and a high of Rs 5.33, the upper circuit price. The stock closed near the high, indicating sustained buying pressure throughout the session. Circuit stocks often exhibit such tight ranges near the ceiling price, as the price band restricts upward movement and sellers remain absent. The narrow range combined with the price lock suggests that demand exceeded what the traded volume could accommodate, reinforcing the presence of unfilled demand.

Brief Fundamental Context

Vivimed Labs Ltd operates in the Pharmaceuticals & Drugs industry, a sector known for its cyclical and regulatory sensitivities. While the stock has been trading near its 52-week lows, the recent surge to the upper circuit may reflect short-term speculative interest rather than a fundamental turnaround. The lack of movement above key moving averages further suggests that the broader market has yet to price in any significant improvement in the company’s fundamentals.

Conclusion: Circuit, Delivery, and Liquidity Signals

The upper circuit hit at Rs 5.33 capped a 5% gain for Vivimed Labs Ltd, with clear evidence of unfilled demand as buyers queued and sellers stayed away. The sharp rise in delivery volumes by over 269% against the 5-day average signals genuine buying interest rather than mere intraday speculation. However, the stock remains below all major moving averages, indicating that the broader trend is still bearish. The micro-cap status and extremely limited liquidity mean that price moves can be exaggerated and difficult to trade in or out of without impacting the price. The circuit locked in gains but also locked out buyers who arrived late — after a 5% single-day gain at upper circuit, is Vivimed Labs Ltd still worth considering or has the move already happened?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today